cms.bioaccessla.com

Tag: anmat

  • ICH E6(R3) Annex 2 Just Hit Step 4 In Rio. Argentina Is Positioned To Be Latin America’s First Adopter. Here’s What That Means For Medtech Sponsors.

    On June 3, 2026, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use convened its biannual Assembly in Rio de Janeiro — the first ICH meeting ever held in Latin America. Brazil’s health regulator, ANVISA, hosted. Among the multiple guidelines under consideration at the meeting, only one was advanced to Step 4 — the final stage of ICH adoption: E6(R3) Annex 2, the guideline that codifies decentralized clinical trial design, pragmatic study architectures, digital health technologies, and real-world data as integral elements of GCP-compliant clinical research.

    For a Latin American clinical research operator that has spent the past sixteen years arguing the case to MedTech, biotech, and radiopharma founders, the June 1 to June 4 sequence in Rio is the most strategically significant positioning event of 2026. The geographic precedent is itself meaningful — ICH governance has historically convened in Geneva, Brussels, Tokyo, or other established regulatory capitals. Selecting Rio de Janeiro and partnering with ANVISA as host signals a structural shift in how ICH governance views Latin American regulatory infrastructure. The substantive outcome — only one guideline elevated to Step 4 at the meeting, and that guideline being the one that defines modern trial design — matters even more for how sponsors will think about LATAM site sequencing over the next 18 to 24 months.

    This post unpacks what Annex 2 actually changes, why the Rio venue matters, and how MedTech sponsors should think about Argentina’s position as the first Latin American jurisdiction structurally ready to accept Annex 2-compliant protocols without amendment.

    What ICH E6(R3) Annex 2 Actually Changes

    ICH E6(R3) is the current Good Clinical Practice (GCP) guideline that all major regulators — FDA, EMA, MHRA, PMDA, Health Canada, and adopting regulators in Latin America — converge on for clinical trial conduct. The most recent revision moved GCP to a risk-based, principle-driven model. Annex 2 extends E6(R3) to explicitly cover the trial designs that have become operational reality over the past five years but lacked formal codification in GCP guidance.

    Specifically, Annex 2 addresses:

    • Decentralized clinical trials (DCTs) — trials where participant interaction with study sites is partially or fully replaced by remote visits, home-based assessments, mobile health units, or telehealth consultations.
    • Pragmatic trial designs — protocols built around real-world clinical settings, with broader patient populations and less restrictive inclusion criteria than traditional efficacy trials.
    • Remote site visits — sponsor monitoring conducted through electronic data review, remote source verification, and risk-based on-site oversight rather than universal in-person visits.
    • Digital health technology (DHT) data capture — continuous glucose monitors, wearable cardiac telemetry, accelerometer-based motion data, smartphone-based patient-reported outcomes, and similar tools used as primary or secondary endpoint capture methods.
    • Real-world data (RWD) — use of electronic health records, claims data, registries, and other non-trial sources as supporting evidence within GCP-compliant studies.
    • Adaptive designs — pre-specified protocol modifications based on accumulating trial data, including sample size re-estimation and arm-dropping decisions.

    The substantive shift in Annex 2 is not new regulation. It is the formal incorporation of these design elements into GCP rather than treating them as exceptions that require special justification. For sponsors who have been building modern trial designs over the past five years, the legal architecture finally caught up with the operational reality.

    Why The Rio Venue Matters

    ICH Assembly meetings rotate among the home jurisdictions of ICH members. Hosting the meeting is a substantive role — the host regulator coordinates logistics, sets the agenda for site-specific discussions, and shapes the framing of how the meeting’s outcomes are communicated to global stakeholders. ANVISA hosting the June 2026 Assembly is the strongest signal to date that Brazilian regulatory infrastructure is converging with ICH governance not as an observer but as an active participant.

    For Brazilian sponsors and CROs, the immediate implication is that ANVISA’s preparation for formal E6(R3) adoption is now visible in a way it was not six months ago. The May 28, 2026 ANVISA board session that explicitly addressed ICH E6 and E8 implementation preparation was the first concrete signal. The June 3 Assembly hosting is the next, much stronger signal. Brazilian formal E6(R3) adoption has no publicly announced timeline yet, but the operational trajectory is no longer in doubt.

    For Argentina, the implication is different but equally substantive. Argentina’s ANMAT, under Disposición 7516/25 operative since December 1, 2025, already maintains a regulatory framework aligned with E6(R3) principles. Argentina did not need to host the Rio Assembly to be ready for Annex 2 — it was already there. What the Rio Assembly does for Argentina is confirm that its regulatory positioning was correctly anticipated, and accelerate the speed at which ANMAT can absorb Annex 2-aligned protocols from sponsors.

    Argentina As The First LATAM Annex 2-Ready Jurisdiction

    Disposición 7516/25 modernized Argentina’s clinical trial framework along several dimensions that align directly with E6(R3) principles: a 62-day parallel ethics and agency review pathway, ICH E6(R3) substantive alignment in protocol structure expectations, and operational mechanisms for risk-based monitoring and remote oversight. Critically for Annex 2, Disposición 7516/25 does not preclude decentralized design elements, DHT data capture, or pragmatic patient populations — it accommodates them.

    The practical consequence is that sponsors designing Annex 2-compliant protocols for FDA or EMA submission in 2026 and 2027 do not face a structural barrier to LATAM site inclusion when Argentina is the lead LATAM jurisdiction. Brazil, Colombia, Mexico, and other LATAM regulators have not formally adopted E6(R3), let alone Annex 2 — meaning protocols built around decentralized or DHT-enabled designs face higher regulatory friction in those jurisdictions until each regulator adopts the guidance domestically.

    For Brazil, the trajectory is unambiguous post-Rio. ANVISA hosting the Assembly, the May 28 board session on E6 and E8 preparation, and the substantive operational alignment between ANVISA’s technovigilance and clinical research frameworks all point toward formal E6(R3) adoption in 2026 or 2027. Annex 2 acceptance follows.

    For Mexico (COFEPRIS), Colombia (INVIMA), and other LATAM regulators, the path is less defined. Colombia’s pending Decreto Único de Dispositivos Médicos e In Vitro (currently in WTO comment phase with a July 17 deadline) introduces international reliance pathways that may indirectly accelerate Annex 2 acceptance, but no formal adoption has been signaled.

    Operational Implications For MedTech Sponsors Designing 2026-2027 Protocols

    For a MedTech sponsor designing a protocol today for a 12 to 18 month FIH-to-pivotal sequence, three operational questions matter immediately.

    First, should the protocol be built Annex 2-compliant from the start? The answer is almost always yes if any of the following apply: DHT-collected endpoints are part of the endpoint set; the patient population is large enough that pragmatic design considerations would materially expand enrollment; remote visits or telehealth consultations would meaningfully reduce participant burden; or the trial design contemplates pre-specified adaptive elements such as sample size re-estimation. Building Annex 2-compliant from the start adds modest protocol-authoring effort and substantial future flexibility.

    Second, how should LATAM country sequencing change? For 2026 and through Q2 2027, Argentina-primary is now the recommended LATAM lead jurisdiction for any Annex 2-aligned design. Disposición 7516/25 is the only operative LATAM framework that can absorb the design without amendment. Brazil-secondary is appropriate as ANVISA formalizes its adoption. Mexico and Colombia remain opportunistic, evaluated on therapeutic-area depth and sponsor-specific operational requirements rather than as primary LATAM hubs for decentralized designs.

    Third, what about sponsors with existing LATAM site relationships built around traditional trial architectures? The Annex 2 guidance does not invalidate traditional trial designs. Sponsors running fully on-site, non-decentralized protocols can continue without adjustment. The shift matters for sponsors whose product strategy is built around DHT-collected endpoints or decentralized data capture — for whom the regulatory architecture in LATAM was previously a bottleneck and now is not.

    What Comes Next

    National regulator implementation of E6(R3) Annex 2 will proceed on independent timelines through 2026 and 2027. FDA has signaled implementation guidance is forthcoming. EMA has indicated alignment without formal adoption schedule. PMDA and Health Canada are expected to follow. In Latin America, ANMAT is positioned to be the first formal adopter, followed by ANVISA. The realistic timeline for ANMAT formal Annex 2 acceptance is Q4 2026 to Q1 2027. ANVISA follows in H1 2027 to H2 2027.

    For sponsors making 2026 country sequencing decisions today, the implication is straightforward. Argentina is positioned as the natural lead LATAM jurisdiction for Annex 2-aligned protocols. Brazil follows. Mexico and Colombia continue to be evaluated case-by-case based on therapeutic-area depth and sponsor-specific requirements.

    The Bottom Line

    Latin America is no longer at the edge of global GCP. The June 3 Rio Assembly, the ANVISA hosting of the meeting, and the Step 4 advancement of E6(R3) Annex 2 together signal a structural shift that sponsors building modern trial designs should integrate into 2026-2027 strategy now rather than after the fact.

    The most expensive country sequencing decision is not the one made wrong. It is the one made too late, after the trial design has been frozen and the regulatory pathway is already constrained by choices that no longer reflect the current landscape.

    If you are evaluating an Annex 2-aligned FIH protocol for 2026 or 2027 and want a LATAM country sequencing analysis that integrates the new Rio Assembly outcomes, the team at bioaccess® can produce a tailored proposal within two weeks. We have run first-in-human and pivotal-stage trials across Argentina, Brazil, Colombia, Mexico, and Panama since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • $8 Billion Of Pharma Capital Just Pointed At Argentina. What Medtech Founders Should Take From The May 29 CAEME Announcement.

    On May 29, 2026, the Cámara Argentina de Especialidades Medicinales (CAEME) announced jointly with President Javier Milei a six-year clinical research investment commitment from seven multinational pharmaceutical companies: Pfizer, Merck, Roche, Novartis, BMS, GSK, and Sanofi. The total commitment is USD 8 billion through 2032. On the same week, ANMAT’s Disposición 2978/2026, which cut import tariffs on medicines and medical devices by 50 to 70 percent, came into operative effect on June 1.

    For a Latin American clinical research operator that has spent 16 years arguing the case to MedTech and biotech founders, the May 29 to June 1 sequence is the strongest sovereign-level signal a Latin American country has produced for clinical research in the past decade. The data and the policy arrived in the same week. The Big Pharma capital and the regulator’s tariff cut arrived in the same week. The case Argentina has been building since Disposición 7516/25 first came into force in 2025 is now publicly endorsed by both seven multinational CEO offices and the federal executive.

    The interesting question is not whether founders should use Argentina for first-in-human (FIH) work. The interesting question is what happens to the Argentine clinical research ecosystem when USD 8 billion of pharma capital flows into a site base that, in 2026, has only 80 to 120 actively credentialed Phase 1/2 sites. This post unpacks the saturation thesis and what early-stage MedTech founders should be doing about it in 2026.

    The Site Saturation Math

    The CAEME pledge of USD 8 billion over 2026 to 2032 implies an average commitment of approximately USD 1.33 billion per year. At industry-average sponsored Phase 1 through 3 trial costs of USD 1 to 3 million per site per year for clinical operations and site fees, the pledge fully funds roughly 430 to 1,330 new trial-site-years annually if disbursed at the announced pace.

    Argentine clinical research currently runs at roughly 290 ANMAT-authorized trials per year (2025 throughput), with 1,188 active studies under ANMAT supervision and approximately 80 to 120 actively credentialed Phase 1/2 sites across all therapeutic areas. The pledge contemplates a 2.5x step-up in trial inflows against approximately the same site base.

    The implication is straightforward. By 2027, Argentine Phase 1/2 site capacity becomes the binding constraint on the system. Regulator throughput, which is already operative at 62 calendar days under Disposición 7516/25, is no longer the rate-limiting step. Site availability is. And site availability at top investigators compresses asymmetrically. A senior PI running three trials in 2026 does not move to six trials in 2027. A senior PI running three trials moves to four trials, while the marginal Phase 1/2 site backlog elongates by 6 to 12 months for the founders arriving last.

    Founders who lock in Argentine site relationships in 2026 are locking in the top quartile of investigators. Founders who arrive in 2027 are competing for what is left after Pfizer, Novartis, and the other CAEME signatories have claimed the senior beds.

    Why the Argentine Government Did This Now

    Three forces converged in 2026 that made the May 29 to June 1 sequence possible. First, the Milei administration’s broader productivity and quality agenda, codified in the proposed PCT (Productividad, Calidad y Transparencia) bill, created the legislative context for industry investment commitments. Second, ANMAT’s operational reform sequence, beginning with Disposición 7516/25 (62-day pathway, parallel ethics plus agency review, ICH E6(R3) alignment), reached a level of regulator credibility that multinationals could underwrite. Third, the comparative landscape moved against Argentina’s peer regulators. Colombia’s Ley 191 stalled in Comisión Séptima and is now effectively dead this term. Brazil’s ICH E6(R3) adoption remains on a slower trajectory than ANVISA’s 2024-2025 board sessions suggested. Mexico’s 30-day target announced at AMIIF on May 19 lacks DOF formalization. Argentina is the only major LATAM jurisdiction in 2026 with operative regulatory reform, operative tariff policy, and operative sovereign-level industry commitment in the same week.

    The PCT bill is the only caveat that matters. The CAEME pledge is contingent on PCT passage. As of June 1, the bill remains stalled. Founders evaluating Argentine sites should treat the regulatory and tariff case as the base case and the CAEME pledge as additive upside. Disposición 7516/25 and Disposición 2978/2026 are in force regardless.

    How to Sequence Argentina in 2026

    The country sequencing decision a MedTech founder makes in 2026 is structurally different than the same decision in 2024. Two years ago, the case for Argentine FIH rested on cost (USD 15,000 to 35,000 per patient versus USD 40,000 to 75,000 in the U.S. and Europe) and regulator throughput (62 days under 7516/25 versus 120 to 180 days under FDA EFS). Both arguments still apply, and the Disposición 2978/2026 tariff cut now removes a 4 to 8 percent additional cost layer on imported devices and study drugs.

    What is new in 2026 is the time pressure. The CAEME pledge does not change the operational case. It changes the urgency of the operational case. A founder who has been considering Argentine site selection for the past six months and has not yet executed is, beginning June 1, 2026, on the wrong side of a closing window. By Q4 2026, the same site relationships will be visibly competitive. By Q2 2027, the top-quartile PI list will be substantively claimed.

    For structural heart and cardiovascular device programs, the recommended sequence is Argentine site selection initiated by Q3 2026, ANMAT protocol filing by Q4 2026, first patient enrolled in Q1 2027. This sequence preserves access to the InCor São Paulo, Hospital Italiano Buenos Aires, and Fundación Cardiovascular Bogotá tier of cardiovascular research centers, with the Argentine arm operating in parallel with a U.S. EFS submission.

    For neuromodulation programs, the recommended sequence compresses further. Site selection at seed close (or post-Series A), ANMAT protocol filing within 90 days of site lock-in. The neuromodulation patient base in Argentina is concentrated at fewer specialized institutions than cardiovascular work, and the saturation pressure on neuromodulation-credentialed PIs is therefore more acute. Founders who have not selected Argentine neuromodulation sites by end of 2026 will likely face 6 to 9 month delays in 2027.

    For radiopharmaceutical and theranostics programs, the operational sequence is different in kind. Site selection has to be scoped before ANY other operational step because of isotope logistics, central pharmacy capacity, and credentialed nuclear medicine institutions. Radiopharma founders who wait until post-acceleration or post-Series A to scope LATAM partners have already added 6 to 9 months to their pivotal timeline. The Argentine radiopharma site base is even more concentrated than the neuromodulation base, and the CAEME pledge is highly likely to direct radiopharma-adjacent investment into the same handful of credentialed institutions.

    What This Means for the Colombia Case

    For bioaccess® and for any founder using a LATAM CRO with Colombian site depth, the May 29 to June 1 sequence forces an honest reassessment. Colombia in 2026 holds the following: established U.S.-trained PI density at specific institutions (Fundación Cardioinfantil, Fundación Valle del Lili, Universidad Javeriana), strong therapeutic-area depth in cardiovascular and oncology, INVIMA throughput at roughly 90 to 120 days. Colombia does not hold: operative sovereign-level investment commitment, modern ICH E6(R3) framework alignment (Resolución 8430/1993 remains the operative framework), or a recent tariff reduction comparable to Disposición 2978/2026.

    The Colombia case for 2026 is no longer “cheaper and faster.” The Colombia case is “specific therapeutic-area depth, U.S.-trained PI networks, and complementarity to an Argentine arm.” For founders running cardiovascular or oncology programs requiring U.S. data acceptance under FDA IDE pathways, the Colombian PI base remains uniquely qualified. For founders running neuromodulation or radiopharmaceutical programs at the FIH stage, the Argentine arm is now the primary recommendation, with Colombian sites operating as the complementary geography rather than the primary geography.

    This is a more nuanced positioning than the one bioaccess® and other LATAM CROs have historically used. It is also the positioning that will hold up over the next 12 to 18 months as the Argentine site saturation pressure builds.

    What Founders Should Do Before End of Q3 2026

    For MedTech, biotech, and radiopharma founders who have not yet scoped their LATAM site portfolio, the practical sequence over the next 90 days looks like:

    First, identify whether the program’s FIH country sequence is Argentina-primary, Argentina-secondary, or Argentina-complementary based on therapeutic area, regulatory pathway, and capital constraints. For structural heart and cardiac ablation, Argentina-primary or Argentina-secondary makes sense. For neuromodulation, Argentina-primary. For radiopharma, Argentina-primary with explicit isotope logistics scoping. For oncology devices with U.S. IDE pathway requirements, Argentina-complementary alongside Colombia or Brazil.

    Second, scope site availability at the institutions most likely to be impacted by the CAEME pledge. The largest pharma signatories (Pfizer, Roche, Novartis) historically work with a specific set of Argentine investigators in cardiology, oncology, and metabolism. Site availability at those investigators will compress first.

    Third, file ANMAT protocols on the Disposición 7516/25 parallel-review pathway. The 62-day timeline allows a 2026 Q3 site selection to produce first-patient-in by year-end. Delays beyond Q3 begin pushing first-patient-in into Q2 2027, by which point the competitive pressure on senior PIs will be visible in enrollment delays.

    Fourth, consider the Disposición 2978/2026 tariff cut as a planning input. The 50 to 70 percent reduction on imported devices and study drugs is most material for early-stage MedTech programs that import 80 to 100 percent of investigational supply. Plan device manufacturing and shipment timing to maximize the tariff savings.

    The Bottom Line

    Argentina did not become a clinical research hub on May 29, 2026. Argentina has been a clinical research hub for 30 years. What happened on May 29 to June 1, 2026, is that the federal executive, the regulator, and seven multinational pharma CEOs publicly aligned on the same operational thesis in the same week. That alignment compresses the founder decision window from years to quarters.

    For early-stage MedTech, biotech, and radiopharma founders evaluating LATAM FIH strategy, the operational reality is that the next 12 to 18 months are a sponsor-favorable market with multiple jurisdictions actively recruiting trial volume. Sponsors who position now benefit from regulator attention, expedited review windows, and access to the senior PI base. Sponsors who delay lose that window.

    The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong country sequence for their specific program. Argentina’s May 29 to June 1 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 LATAM FIH country sequencing decision and want a tailored proposal that incorporates the new ANMAT regulatory and tariff environment alongside Colombian and Brazilian complementary site options, the team at bioaccess® can produce a country-level model within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Argentina Just Cut Clinical Trial Import Costs By 50 70%. Here’s What 290 Authorized Trials In 2025 Tell Founders.

    On May 19, 2026, Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) published Disposición 2978/2026, cutting import tariffs on medicines and medical devices by 50 to 70 percent, effective June 1, 2026. The preamble of the instrument states the policy goal explicitly: to attract clinical trial investment to Argentina. The next day, the Argentine government released throughput data that explained why the policy was built: 290 clinical trials authorized in 2025, a 12 percent year-over-year increase, with 114 already authorized in the first quarter of 2026 and 1,188 active studies under ANMAT supervision. Argentina is now formally branding itself an “internationally competitive clinical research hub.”

    For a Latin American clinical research operator who has spent 16 years arguing the speed-and-cost case to MedTech and biopharma founders, the May 19-20 sequence is the most unusual validation event the regulatory landscape has produced this decade. Most LATAM clinical research positioning is CRO marketing. Argentina’s came from the regulator itself, in the preamble of a binding instrument, on government letterhead, with throughput numbers attached. That is not the same kind of evidence as a competitive pitch deck.

    For founders running a 10-patient first-in-human (FIH) device study, the math now stacks in a way that materially changes the country sequencing decision. This post unpacks what changed, what stayed the same, and how founders pursuing a U.S. Early Feasibility Studies (EFS) plus out-of-U.S. (OUS) FIH strategy should think about Argentina in 2026.

    What Changed on May 19, 2026

    Disposición 2978/2026 is the binding instrument. The tariff reduction applies across the import basket relevant to clinical research operations, including investigational drugs, medical devices in trial-supply quantities, reference standards, and disposable consumables tied to study protocols. The pre-existing effective duty rate for imported medical devices in Argentina ranged from 12 to 18 percent before May 19. Under the new schedule, that effective rate compresses to roughly 6 to 12 percent for trial-supply imports, with category-specific reductions ranging from 50 to 70 percent depending on the harmonized system classification.

    On its own, the tariff cut is meaningful. It is more meaningful in combination with the operational baseline Argentina already had in place. Disposición 7516/2025, which came into force in 2025 and is fully aligned with ICH E6(R3), caps clinical trial protocol authorization at 62 calendar days (45 working days maximum). That includes parallel ethics committee review and ANMAT agency review, not sequential review. For comparison, the U.S. EFS pathway typically runs 120 to 180 days from IDE submission to first patient enrolled. Argentina’s ANMAT pathway is 60 to 120 days faster, depending on the comparison case.

    The April 24, 2026 importación simplification further compresses pre-first-patient timelines by removing roughly 14 to 21 days of customs and import-classification delay that previously sat between protocol approval and the actual arrival of study material at site. The June 1, 2026 tariff reduction now removes the cost penalty that previously sat alongside that delay.

    The Throughput Number Most Founders Miss

    The 290-trials-in-2025 figure deserves more attention than it has received. Of those 290 authorizations, the regulator-reported mix is approximately 70 percent biopharma and 30 percent medical device or combination product. The Q1 2026 pace of 114 authorizations annualizes to roughly 456 trials per year, which would represent a 57 percent year-over-year acceleration if sustained. Even if the run rate moderates by half, Argentina’s 2026 throughput will exceed all prior years on record.

    For a founder evaluating site capacity risk, the 1,188 active studies under ANMAT supervision is the more strategic data point. Argentina has the patient-volume depth and the principal-investigator network density to absorb new sponsor demand without the recruitment friction that emerging-market sites with thinner trial histories often impose. A FIH MedTech sponsor running a 10-patient study at two Argentine sites can realistically expect first-patient-in within 90 days of protocol approval, and last-patient-in within 5 to 7 months of contract execution. Those numbers have been stable across the last 36 months of bioaccess® operational experience.

    The Cost Math, Refreshed

    Pre-May 19, 2026, the LATAM per-patient cost range for a FIH MedTech study sat at $15,000 to $35,000, compared to $40,000 to $75,000 in the U.S. and Europe. For a 10-patient FIH device study, that is a $250,000 to $400,000 absolute swing, sufficient on its own to fund roughly four months of clinical operations headcount or a complete adaptive design biostatistics package.

    The June 1 tariff reduction does not move the per-patient labor cost. It moves the device and drug-import cost component, which typically represents 8 to 15 percent of total study cost for a MedTech FIH trial relying on imported investigational devices. A 50 percent reduction on that line item produces a 4 to 8 percent reduction on total study cost, which compounds with the labor cost advantage Argentina already offered. On a $250,000 study, that is an additional $10,000 to $20,000 of effective savings. On a $1 million pivotal-stage Argentine arm of a multi-country trial, the effect grows proportionally.

    The strategic value is not the headline savings number. It is the regulatory clarity that the tariff cut produces. Sponsors evaluating Argentina now know that the regulator has formally committed to clinical research as a strategic policy priority. That changes how a CFO evaluates jurisdiction risk in the IND-enabling phase.

    The Database Anomaly and How to Work Around It

    One operational caveat is worth flagging directly. ANMAT’s public pharmacology database, which historically served as the citable reference for trial throughput and status, remains anchored at a September 30, 2025 data cutoff. As of the publication date of this post, that anomaly has persisted for four consecutive weekly review cycles. The most likely explanation is a backend migration tied to the broader Argentine government’s digital transformation initiative, but the database itself does not yet reflect Q4 2025 or any 2026 data.

    For sponsors building a regulatory dossier or a board pack that requires citable Argentine clinical research throughput data, the May 20, 2026 government statistics package, available through argentina.gob.ar communications channels, is now the more authoritative source than the database. For real-time individual study status, the RENIS (Registro Nacional de Investigaciones en Salud) registry, accessible through the SISA portal, remains operative and current. Disposición 7516/25, the 62-day pathway, the importación simplification, and Disposición 2978/2026 are all fully in force regardless of the database refresh status.

    How to Sequence Argentina in a U.S. EFS Plus OUS FIH Strategy

    The most common 2026 founder question is whether to run U.S. EFS first, OUS FIH first, or both in parallel. The May 19-20 Argentina updates do not change the answer in every case, but they change it in enough cases that the question is worth re-examining.

    For structural heart, neuromodulation, and radiopharmaceutical or theranostic FIH programs, where the U.S. EFS pathway involves an IDE submission with 120 to 180 day review timelines, the parallel Argentina arm is now substantially more attractive. The argument runs as follows: a sponsor who files the IDE with FDA in month one and simultaneously files the ANMAT protocol under Disposición 7516/25 will, in a typical case, have ANMAT approval and first-patient-in achieved before the FDA has finished its initial IDE review. That bridge data, if collected against an FDA-aligned endpoint set, materially strengthens the IDE review and accelerates the post-IDE clinical trial path.

    The bridge data approach assumes the sponsor designs the Argentine arm to match the FDA-expected endpoints from the outset. That is not a regulatory obligation in Argentina, but it is the operational discipline that converts a 62-day pathway into a strategic asset rather than a parallel cost center. ICH M11 CeSHarP, finalized by ICH on May 21, 2026, makes that endpoint-aligned protocol authoring substantially more efficient than it was a year ago.

    For absorbable implants, cardiac ablation, and oncology device FIH programs, the Argentina arm makes sense as the primary FIH site set, with the U.S. EFS following as a confirmatory phase rather than as the primary first-in-human exposure. The 2026 tariff reduction further tips the math in this direction for sponsors with capital constraints between Series A and Series B.

    What This Means for the Latin American Clinical Research Landscape

    Argentina’s May 19-20 sequence is the clearest example to date of a Latin American regulator choosing, in policy, to compete for clinical research investment. Brazil, Mexico, and Colombia have made similar moves in the past 24 months, but none have packaged a binding tariff reduction with a coordinated government statistics release in the same week. The combination is what makes the Argentine moment unusual.

    For Latin American CROs, the strategic implication is that the next 12 to 18 months will likely be a sponsor-favorable market, with multiple jurisdictions actively recruiting trial volume. Sponsors who position now will benefit from regulator attention, expedited review windows, and the willingness of agencies to engage with novel trial designs at the pre-submission stage. Sponsors who delay until the policy environment has fully stabilized will lose the strategic window.

    For bioaccess® and other LATAM operators, the implication is that the value proposition has moved beyond cost and speed into regulatory partnership. The conversation a founder needs to have with their CRO in 2026 is no longer about how fast the trial can run. It is about how the trial design, the country sequence, and the data architecture combine to compress the Innovation Runway, the operational window between a founder’s first FIH decision and the data package their next funding round requires.

    The Bottom Line for Founders

    Argentina has just made the clearest policy statement any Latin American clinical research regulator has produced in 2026. The 62-day pathway under Disposición 7516/25 is operative. The importación simplification is in force. The 50 to 70 percent tariff reduction on imported medicines and medical devices begins June 1. The throughput data confirms that the regulatory environment can absorb new sponsor demand at scale.

    For a MedTech, biotech, or radiopharma founder evaluating a 2026 FIH country sequencing decision, the Argentine arm now warrants serious consideration as the lead site or the parallel site for any program where the U.S. EFS pathway is the comparison baseline. The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong study to run first. Argentina’s May 19-20 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 FIH sequencing decision and want a country-level model that reflects the new Argentina policy environment, the team at bioaccess® can produce a tailored proposal within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Regulatory Harmonization in Latin America: What ANVISA’s Regional Cooperation Signals for Multi‑Country MedTech Trials

    Regulatory Harmonization in Latin America: What ANVISA’s Regional Cooperation Signals for Multi‑Country MedTech Trials

    Latin America is not a single regulatory market, but the region is moving toward more structured cooperation, reliance, and convergence. For MedTech sponsors running multi-country clinical programs, these shifts matter because they can change how dossiers are prepared, how evidence is reused, and how activation risks are managed.

    In June 2026, ANVISA reported participating in a PAHO-organized Regional National Regulatory Reference Authorities (NRAr) meeting in Buenos Aires focused on strengthening regulatory systems and expanding international cooperation. ANVISA also described bilateral discussions with multiple agencies (including FDA, Cofepris, Anmat, and Invima) and highlighted signing a memorandum of understanding with Colombia’s regulator to enable confidential information exchange and support reliance initiatives.

    These developments do not eliminate country-by-country requirements. However, they signal a direction of travel: more formal cross-border collaboration, more alignment on good regulatory practices, and potentially more predictability for sponsors who plan strategically.

    1) Why “harmonization” matters for MedTech trial execution (not just strategy)

    When teams hear “regulatory harmonization,” they often think of policy. Operationally, the real value comes from:

    • Reuse of core evidence packages across multiple authorities
    • Fewer contradictory requirements that force protocol redesign
    • More predictable review expectations when agencies align with shared standards
    • Reduced activation friction when documentation formats converge

    For early-stage MedTech sponsors, reducing friction is not a luxury. It can be the difference between hitting a funding milestone and needing a bridge round.

    2) What ANVISA’s recent cooperation activity suggests

    ANVISA’s public update indicates three practical signals for sponsors:

    • Regional capacity-building is a priority: the NRAr meeting agenda included mechanisms for convergence and innovation, plus updates to PAHO’s regional policy for strengthening regulatory systems.
    • Reliance is becoming more explicit: ANVISA described an agreement with Colombia’s regulator to enable confidential information exchange and support reliance initiatives.
    • Global credibility is a strategic goal: ANVISA highlighted progress toward WHO Listed Authority (WLA) recognition, which can influence how other stakeholders view Brazilian regulatory decisions.

    None of this means that a sponsor can file once and be approved everywhere. But it does mean sponsors should expect more structured cooperation and should design their evidence and documentation to be “portable.”

    3) How to design a “portable dossier” for Latin America

    A portable dossier is not a one-size-fits-all PDF. It is a controlled set of core modules that can be adapted with minimal rework. Practical components include:

    • Master protocol with annex-ready country adaptations (contact details, lab references, safety reporting specifics)
    • Device description and risk analysis aligned to internationally recognized principles (clear intended use, hazards, mitigations)
    • Clinical evaluation narrative that ties early feasibility data to the next evidence step
    • Quality and traceability package that supports import, accountability, and post-trial device handling

    The goal is to reduce “translation churn”—not just language translation, but repeated rewriting driven by different templates.

    4) Planning multi-country activation under partial convergence

    Even with convergence, activation remains a network problem. Practical planning considerations include:

    • Choose an anchor country with predictable timelines and strong sites to generate early momentum.
    • Open a second wave in parallel where operational readiness is high and import pathways are clear.
    • Use timeline intelligence from authoritative resources: for example, NIH ClinRegs summarizes that Brazil’s Law No. 14.874 sets a 90-business-day deadline for ANVISA’s analysis of primary petitions for clinical trials, while Peru’s INS must complete review and approval of a clinical trial application within a maximum of 30 working days.

    These published timelines are not the entire story, but they are a useful starting point for scenario planning and stakeholder alignment.

    5) What to watch next (and how to stay ahead)

    Regulatory convergence tends to move in “bursts,” driven by new policies, pilot programs, and bilateral agreements. Sponsors can stay ahead by:

    • Monitoring regulator cooperation news from agencies and PAHO
    • Building evidence packages that align with shared standards so they remain reusable as convergence increases
    • Running pre-activation risk reviews that consider import, ethics, and site readiness in each target country

    The most successful teams treat regulatory strategy as an operational lever. Convergence is valuable, but only if you translate it into a concrete activation plan.

    FAQ: Regulatory harmonization and multi-country trials in Latin America

    Is Latin America becoming a single regulatory market for MedTech trials?

    No. Each country retains its own laws and authorities. However, cooperation and convergence efforts can reduce friction and improve predictability over time.

    What recent sign suggests increased cooperation?

    ANVISA publicly described participating in PAHO’s NRAr meeting in Buenos Aires and reported signing a memorandum of understanding with Colombia’s regulator to enable confidential information exchange and support reliance initiatives.

    How should sponsors respond today?

    Design a portable dossier, plan activation as parallel workstreams, and sequence countries based on both published timelines and on-the-ground operational readiness.

    Bottom line: regulatory harmonization is not a shortcut, but it is a trend sponsors can operationalize. Teams that build portable evidence and plan multi-country activation around predictable processes will be best positioned as convergence accelerates.

  • Argentina’s $8 Billion Clinical Research Commitment: What It Means For Medtech Startup FIH Trials In 2026

    Argentina’s $8 Billion Clinical Research Commitment: What It Means for MedTech Startup FIH Trials in 2026

    By Julio Martinez-Clark, CEO, bioaccess® | June 2026

    The Signal That Most MedTech Founders Missed

    In late May 2026, seven of the world’s largest pharmaceutical companies — Pfizer, Merck, Roche, Novartis, Bristol Myers Squibb, GSK, and Sanofi — pledged a combined $8 billion in Argentine clinical research investment over the 2026–2032 period. Days later, Argentina’s national drug and food regulator, ANMAT, published Disposición 2978/2026, cutting import tariffs on medicines and medical devices by 50 to 70 percent, effective June 1, 2026.

    The pharma industry picked up the $8 billion figure immediately. MedTech largely did not. That gap is worth examining — because for a structural heart, neuromodulation, or radiopharmaceuticals startup planning a first-in-human (FIH) trial in the next 18 months, these two policy events together represent one of the most significant shifts in the LATAM early-phase clinical research environment in a decade.

    This piece walks through what actually changed, why it matters specifically for device and biotech FIH programs, and how to think about Argentina as part of a first-in-human trial site strategy in 2026.

    What Changed: Disposición 2978/2026 and the $8B Commitment

    The Tariff Reduction

    Disposición 2978/2026 is not a pilot, a phase-in, or a proposed amendment — it is in effect. Import tariffs on medicines and medical devices were reduced by 50 to 70 percent, effective June 1, 2026. For a device company running an FIH feasibility study, this has a direct, calculable effect on budget: investigational devices entering Argentina for clinical use carry materially lower landed cost.

    In early-phase device trials, the investigational product is often the single largest variable cost item outside of site and monitoring fees. A 50 percent reduction in import tariffs on a novel transcatheter device, for example, can change the per-patient cost model meaningfully — particularly for seed-stage and Series A sponsors working with sub-$15 million clinical trial budgets.

    The tariff change also simplifies regulatory logistics. One of the historically cited friction points in Argentine FIH trials has been the import authorization process for investigational devices that were not commercially registered in Argentina. Lower tariff classification, combined with ANMAT’s active throughput cadence, reduces one layer of that friction.

    The $8 Billion Pharma Commitment

    The $8 billion multi-company pledge is not a single infrastructure project — it represents committed clinical research spend across seven major sponsors over six years. The practical implications:

    • Site infrastructure: When Pfizer, Roche, and Novartis are committing multi-year research spend to Argentina, they are investing in investigator networks, clinical infrastructure, and regulatory capacity at sites. This infrastructure — trained investigators, GCP-compliant facilities, ethics committees with high-volume experience — is precisely what a MedTech startup needs for an FIH feasibility study.
    • Regulatory capacity: ANMAT’s workload will increase, but so will its institutional capacity. Regulators that process high volumes of multi-national submissions develop faster, more predictable review cycles. Argentina approved 290 new clinical studies in 2025, an 8 percent year-over-year increase, with more than 1,000 active trials and 50,000+ participants enrolled. The $8 billion commitment is a signal that this trajectory accelerates.
    • International credibility: Large pharma’s visible commitment to Argentina as a clinical research destination reduces the country risk perception that smaller device sponsors sometimes encounter when presenting LATAM FIH data to US investors and regulatory reviewers.

    Practical Considerations for MedTech Sponsors

    A realistic timeline from engagement to first patient for a novel device FIH study in Argentina: Weeks 1–4 site identification; Weeks 5–8 ethics committee; Weeks 6–12 ANMAT authorization; Weeks 10–16 site initiation; Weeks 14–20 first patient in. The Argentina FIH environment also benefits from bioaccess® multi-country capability covering Argentina and Colombia as primary FIH jurisdictions.

    Sources

  • Argentina And Colombia Just Signed A Regulatory Mou. Here’s What That Means For Medtech Sponsors Running Multi-Country LATAM Trials.

    The Headline

    On June 13, 2026, Argentina’s ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) and Colombia’s INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) signed a Memorandum of Understanding that formalizes bilateral cooperation across medicines, food, and medical devices. The text was published on the INVIMA portal the same day. [INVIMA]

    For sponsors running, planning, or sequencing multi-country clinical programs in Latin America, this matters more than the typical regulatory press release. It is the most operationally consequential change to the Argentina-Colombia regulatory interface since 2018 — and it lands at the exact moment Colombia is finalizing its Decreto Único de Dispositivos Médicos and Argentina is operationalizing ICH E6(R3) Annex 2.

    This article walks through what the MoU actually establishes, what it does not establish, and how MedTech and Biopharma sponsors should sequence their LATAM trials in light of it.

    What The MoU Actually Says

    The June 13 instrument is short on legal flourish and dense on operational substance. Stripped to its four working pillars, the MoU establishes:

    1. Information exchange across regulated categories — covering registration dossiers, surveillance signals, and inspection findings.
    2. Protocol and best-practices sharing — methodologies, technical guidance, and procedural alignment on common review pathways.
    3. Joint project collaboration — coordinated capacity-building initiatives, training exchanges, and technical mission programming.
    4. Confidentiality and monitoring framework — formal governance of how shared data is handled and how cooperative activities are tracked over time.

    The cooperation explicitly covers medicines, food, and medical devices. That last category is the one many sponsors miss. The 2014 and 2018 instruments between the two agencies were narrower — 2014 focused on “exchange of experiences and good practices,” and 2018 was specifically about Good Manufacturing Practice inspection records. The 2026 MoU is the first comprehensive framework that unifies the medical device dimension with pharmaceuticals and food under a single working architecture. [ANMAT Cooperation Registry]

    What The MoU Does Not Do

    Three clarifications worth front-loading, because we are already seeing them misunderstood in early secondary commentary.

    The MoU does not create single-window approvals. A sponsor preparing a clinical trial in both Argentina and Colombia still files two separate dossiers, with two separate regulatory teams, on two distinct timelines. ANMAT continues to operate Disposición 7516/25 and the Resolution 1480/2011 ethics framework. INVIMA continues to operate under Decreto 4725 de 2005 and Resolución 1229 de 2013 until the new Decreto Único is published.

    The MoU does not formalize automatic reliance. Reliance — where one regulator can lean on another’s scientific assessment to shorten its own review — exists as a regulatory principle in both agencies’ modernization agendas, but the MoU itself does not create a reliance pathway between them. It creates the plumbing through which such pathways can later be built.

    The MoU does not change cost or fee structures. Sponsors should not expect this instrument to reduce regulatory review fees, ethics committee charges, or local sponsor representation costs in either jurisdiction.

    What It Does, In Practice

    What the MoU does, immediately, is formalize four operational improvements that previously depended on ad-hoc coordination through ICH Assembly hallway conversations and the International Pharmaceutical Regulators Programme (IPRP) plenary sessions.

    One. When a sponsor’s submission triggers a safety signal in one country, that signal can now flow through a structured channel to the other regulator within a defined confidentiality envelope. Before this MoU, a sponsor with a flagged adverse event in Argentina would typically receive an independent inquiry from Colombia weeks or months later, often duplicating the original investigation. After this MoU, the two regulators can coordinate the inquiry’s timing and scope.

    Two. Inspection of a sponsor or manufacturer operating in both jurisdictions can be coordinated. A single inspection mission, with two regulators present or with shared inspection reporting, materially compresses the sponsor’s compliance overhead.

    Three. Capacity-building and training activities — pharmacovigilance, tecnovigilancia, quality risk management — can be conducted jointly. This raises the technical floor in both countries, which is good for sponsors because the predictable downside of trial expansion to a smaller-budget regulator is technical inconsistency at the review level.

    Four. Standards and review methodologies can be aligned over time. The MoU does not specify which standards or methodologies, but it creates the working group structure to negotiate them. The most likely early candidates are software-as-a-medical-device classification, AI/ML model change pathways, and harmonization of IMDRF-aligned UDI requirements.

    The Decreto Único Context

    The MoU lands during one of the most active periods of Colombian medical device regulatory reform in two decades. Colombia’s Decreto Único de Dispositivos Médicos — a 16-chapter, 180-article instrument that consolidates and replaces Decretos 4725/2005 and 3770/2004 — completed its national public consultation phase and entered WTO international consultation on May 18, 2026. The comment window closes July 17, 2026. [CONSULTORSALUD]

    INVIMA’s Director of Medical Devices and Other Technologies, Doris Yolima Gómez Parada, has been publicly explicit about the substantive direction: indefinite-validity authorizations (conditioned on post-market performance), strengthened tecnovigilancia, mandatory Unique Device Identification (UDI) at initial registration, IMDRF-aligned risk classification (three classes expanding to four), and an explicit reliance framework that recognizes FDA, EMA, and ANVISA assessments — supplemented by Pacific Alliance, Rio Accord, and WHO Listed Authority qualifications.

    For a multi-country sponsor, the implication is direct: the Decreto Único modernizes Colombia’s regulatory architecture in ways that are structurally compatible with Argentina’s ICH E6(R3) Annex 2 adoption. The June 13 MoU is the procedural connective tissue between the two modernizations.

    The Argentina Side: ICH Annex 2 Operative

    Argentina entered this MoU from a position of unusual regulatory strength. ANMAT adopted the ICH E6(R3) operative framework under Disposición 7516/25, and Annex 2 — the risk-proportionate quality management addendum — was finalized to Step 4 at the ICH Assembly in Rio de Janeiro on June 3, 2026, two weeks before the MoU was signed. ANMAT confirmed participation in both the ICH Assembly and the IPRP sessions of June 3-4.

    Argentina’s documented FIH timeline benchmark currently sits at 62 days from study start to first patient enrolled, inclusive of ethics committee review, ANMAT regulatory authorization, and clinical site activation. That benchmark assumes a well-prepared sponsor working with operational sites in greater Buenos Aires, La Plata, Mendoza, and Rosario.

    The MoU’s value to an Argentina-primary sponsor is that secondary expansion into Colombia — historically a separate operational track with limited information continuity — now sits on a coordinated information channel. The Decreto Único’s reliance pathway, once operational, can in principle leverage Argentina-generated dossier work for parts of the Colombian submission.

    Practical Implications: How To Sequence A Multi-Country Trial Now

    For a MedTech, Biopharma, or Radiopharma sponsor planning a 2026-2027 LATAM trial, the operational sequencing question changes in three ways.

    Argentina-primary sequencing is now operationally cleaner. If your indication has equivalent patient availability in both Argentina and Colombia, starting in Argentina has three compounding advantages: ICH E6(R3) Annex 2 inspection-readiness, a 62-day study start timeline, and — under the MoU — a smoother information bridge into Colombia for the secondary expansion.

    Colombia is no longer a second-tier choice for sponsors with cardiovascular, oncology, or rare-disease indications. The combination of the MoU plus the Decreto Único’s reliance framework plus Colombia’s IMDRF affiliate member status (effective September 2025) materially raises Colombia’s strategic value. The five-month Colombian FIH timeline that has been the benchmark for the past three years will compress meaningfully once the Decreto Único is in force.

    The IRB and ethics committee dimension matters more, not less. The MoU does not touch independent ethics committee review. Sponsors gain little if their Argentine site is approved in 62 days and the Colombian ethics committee for a comparable indication takes four months. Operational selection of ethics committees with proven turnaround for the relevant therapeutic area becomes a larger fraction of the timeline gap.

    What To Watch Between Now And September

    Four watch items will determine how much of the MoU’s potential operational value crystallizes in 2026.

    July 17: The WTO comment window on the Decreto Único closes. Industry comment density and the substance of the final text will shape whether reliance is operationally meaningful or a paper provision.

    Late Q3 2026: Implementing language for the MoU. The instrument as signed is a framework. Working-group structure, the first joint technical projects, and any joint training program will signal how seriously both agencies intend to execute on the framework.

    Q4 2026: Decreto Único publication. The 18-month transition period for industry begins on publication. Sponsors should plan for a 2027 implementation horizon for the new Colombian regime.

    2027 onward: First coordinated inspection. If ANMAT and INVIMA execute a coordinated inspection of a sponsor or manufacturer operating in both countries, that becomes the case study that defines the MoU’s operational reality.

    Why This Matters For Operating At Scale In LATAM

    We have been operating multi-country clinical programs in Latin America since 2010. Across 47 first-in-human studies for MedTech, Biopharma, and Radiopharma sponsors, the practical bottleneck in expanding from a single-country trial to a regional program has rarely been regulatory text. It has been the discontinuities between regulators — different document formats, divergent timing assumptions, ethics committees that interpret international guidance differently, and the absence of any structured channel for coordinating safety information when a study runs in parallel in two jurisdictions.

    The MoU is the first instrument in our operating memory that addresses those discontinuities directly. It does not eliminate them. It builds the architecture inside which they can be addressed deliberately, instead of through ad-hoc coordination at ICH meetings.

    For sponsors evaluating LATAM right now, the immediate practical advice is: do not wait. The MoU’s value compounds for sponsors who establish operational presence in both Argentina and Colombia before the implementing language is in place — because those sponsors will be the test cases that shape how the MoU actually works. By the time the framework is mature, the operational advantage will have moved downstream.

    The Bottom Line

    The Argentina-Colombia MoU of June 13, 2026, does not change clinical trial regulation in either country. It changes the operating architecture between them. For multi-country LATAM sponsors, that architecture is the part of the regulatory environment that has been hardest to manage, and it is the part that has been most resistant to structural improvement.

    If your 2026-2027 strategic plan included evaluating LATAM as a multi-country option for an FIH or early-feasibility study, the case just got materially stronger. If your plan did not include LATAM, the regulatory ceiling that previously made multi-country expansion operationally difficult has been formally lifted.

    The two LATAM regulators with the deepest reform agendas in the region just connected their working architecture. The sponsors who move first will define what the connection means.

    bioaccess® is a clinical research organization purpose-built for first-in-human and early-phase studies for MedTech, Biopharma, and Radiopharma startups in Latin America. We have supported 47 FIH programs since 2010 across Argentina, Brazil, Colombia, Mexico, Costa Rica, and Panama. To discuss a multi-country LATAM trial strategy, contact us at info@bioaccessla.com or visit bioaccessla.com/roadmap.

  • ICH E6(R3) Annex 2 Just Hit Step 4 In Rio. Argentina Is Positioned To Be Latin America’s First Adopter. Here’s What That Means For Medtech Sponsors.

    On June 3, 2026, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use convened its biannual Assembly in Rio de Janeiro — the first ICH meeting ever held in Latin America. Brazil’s health regulator, ANVISA, hosted. Among the multiple guidelines under consideration at the meeting, only one was advanced to Step 4 — the final stage of ICH adoption: E6(R3) Annex 2, the guideline that codifies decentralized clinical trial design, pragmatic study architectures, digital health technologies, and real-world data as integral elements of GCP-compliant clinical research.

    For a Latin American clinical research operator that has spent the past sixteen years arguing the case to MedTech, biotech, and radiopharma founders, the June 1 to June 4 sequence in Rio is the most strategically significant positioning event of 2026. The geographic precedent is itself meaningful — ICH governance has historically convened in Geneva, Brussels, Tokyo, or other established regulatory capitals. Selecting Rio de Janeiro and partnering with ANVISA as host signals a structural shift in how ICH governance views Latin American regulatory infrastructure. The substantive outcome — only one guideline elevated to Step 4 at the meeting, and that guideline being the one that defines modern trial design — matters even more for how sponsors will think about LATAM site sequencing over the next 18 to 24 months.

    This post unpacks what Annex 2 actually changes, why the Rio venue matters, and how MedTech sponsors should think about Argentina’s position as the first Latin American jurisdiction structurally ready to accept Annex 2-compliant protocols without amendment.

    What ICH E6(R3) Annex 2 Actually Changes

    ICH E6(R3) is the current Good Clinical Practice (GCP) guideline that all major regulators — FDA, EMA, MHRA, PMDA, Health Canada, and adopting regulators in Latin America — converge on for clinical trial conduct. The most recent revision moved GCP to a risk-based, principle-driven model. Annex 2 extends E6(R3) to explicitly cover the trial designs that have become operational reality over the past five years but lacked formal codification in GCP guidance.

    Specifically, Annex 2 addresses:

    • Decentralized clinical trials (DCTs) — trials where participant interaction with study sites is partially or fully replaced by remote visits, home-based assessments, mobile health units, or telehealth consultations.
    • Pragmatic trial designs — protocols built around real-world clinical settings, with broader patient populations and less restrictive inclusion criteria than traditional efficacy trials.
    • Remote site visits — sponsor monitoring conducted through electronic data review, remote source verification, and risk-based on-site oversight rather than universal in-person visits.
    • Digital health technology (DHT) data capture — continuous glucose monitors, wearable cardiac telemetry, accelerometer-based motion data, smartphone-based patient-reported outcomes, and similar tools used as primary or secondary endpoint capture methods.
    • Real-world data (RWD) — use of electronic health records, claims data, registries, and other non-trial sources as supporting evidence within GCP-compliant studies.
    • Adaptive designs — pre-specified protocol modifications based on accumulating trial data, including sample size re-estimation and arm-dropping decisions.

    The substantive shift in Annex 2 is not new regulation. It is the formal incorporation of these design elements into GCP rather than treating them as exceptions that require special justification. For sponsors who have been building modern trial designs over the past five years, the legal architecture finally caught up with the operational reality.

    Why The Rio Venue Matters

    ICH Assembly meetings rotate among the home jurisdictions of ICH members. Hosting the meeting is a substantive role — the host regulator coordinates logistics, sets the agenda for site-specific discussions, and shapes the framing of how the meeting’s outcomes are communicated to global stakeholders. ANVISA hosting the June 2026 Assembly is the strongest signal to date that Brazilian regulatory infrastructure is converging with ICH governance not as an observer but as an active participant.

    For Brazilian sponsors and CROs, the immediate implication is that ANVISA’s preparation for formal E6(R3) adoption is now visible in a way it was not six months ago. The May 28, 2026 ANVISA board session that explicitly addressed ICH E6 and E8 implementation preparation was the first concrete signal. The June 3 Assembly hosting is the next, much stronger signal. Brazilian formal E6(R3) adoption has no publicly announced timeline yet, but the operational trajectory is no longer in doubt.

    For Argentina, the implication is different but equally substantive. Argentina’s ANMAT, under Disposición 7516/25 operative since December 1, 2025, already maintains a regulatory framework aligned with E6(R3) principles. Argentina did not need to host the Rio Assembly to be ready for Annex 2 — it was already there. What the Rio Assembly does for Argentina is confirm that its regulatory positioning was correctly anticipated, and accelerate the speed at which ANMAT can absorb Annex 2-aligned protocols from sponsors.

    Argentina As The First LATAM Annex 2-Ready Jurisdiction

    Disposición 7516/25 modernized Argentina’s clinical trial framework along several dimensions that align directly with E6(R3) principles: a 62-day parallel ethics and agency review pathway, ICH E6(R3) substantive alignment in protocol structure expectations, and operational mechanisms for risk-based monitoring and remote oversight. Critically for Annex 2, Disposición 7516/25 does not preclude decentralized design elements, DHT data capture, or pragmatic patient populations — it accommodates them.

    The practical consequence is that sponsors designing Annex 2-compliant protocols for FDA or EMA submission in 2026 and 2027 do not face a structural barrier to LATAM site inclusion when Argentina is the lead LATAM jurisdiction. Brazil, Colombia, Mexico, and other LATAM regulators have not formally adopted E6(R3), let alone Annex 2 — meaning protocols built around decentralized or DHT-enabled designs face higher regulatory friction in those jurisdictions until each regulator adopts the guidance domestically.

    For Brazil, the trajectory is unambiguous post-Rio. ANVISA hosting the Assembly, the May 28 board session on E6 and E8 preparation, and the substantive operational alignment between ANVISA’s technovigilance and clinical research frameworks all point toward formal E6(R3) adoption in 2026 or 2027. Annex 2 acceptance follows.

    For Mexico (COFEPRIS), Colombia (INVIMA), and other LATAM regulators, the path is less defined. Colombia’s pending Decreto Único de Dispositivos Médicos e In Vitro (currently in WTO comment phase with a July 17 deadline) introduces international reliance pathways that may indirectly accelerate Annex 2 acceptance, but no formal adoption has been signaled.

    Operational Implications For MedTech Sponsors Designing 2026-2027 Protocols

    For a MedTech sponsor designing a protocol today for a 12 to 18 month FIH-to-pivotal sequence, three operational questions matter immediately.

    First, should the protocol be built Annex 2-compliant from the start? The answer is almost always yes if any of the following apply: DHT-collected endpoints are part of the endpoint set; the patient population is large enough that pragmatic design considerations would materially expand enrollment; remote visits or telehealth consultations would meaningfully reduce participant burden; or the trial design contemplates pre-specified adaptive elements such as sample size re-estimation. Building Annex 2-compliant from the start adds modest protocol-authoring effort and substantial future flexibility.

    Second, how should LATAM country sequencing change? For 2026 and through Q2 2027, Argentina-primary is now the recommended LATAM lead jurisdiction for any Annex 2-aligned design. Disposición 7516/25 is the only operative LATAM framework that can absorb the design without amendment. Brazil-secondary is appropriate as ANVISA formalizes its adoption. Mexico and Colombia remain opportunistic, evaluated on therapeutic-area depth and sponsor-specific operational requirements rather than as primary LATAM hubs for decentralized designs.

    Third, what about sponsors with existing LATAM site relationships built around traditional trial architectures? The Annex 2 guidance does not invalidate traditional trial designs. Sponsors running fully on-site, non-decentralized protocols can continue without adjustment. The shift matters for sponsors whose product strategy is built around DHT-collected endpoints or decentralized data capture — for whom the regulatory architecture in LATAM was previously a bottleneck and now is not.

    What Comes Next

    National regulator implementation of E6(R3) Annex 2 will proceed on independent timelines through 2026 and 2027. FDA has signaled implementation guidance is forthcoming. EMA has indicated alignment without formal adoption schedule. PMDA and Health Canada are expected to follow. In Latin America, ANMAT is positioned to be the first formal adopter, followed by ANVISA. The realistic timeline for ANMAT formal Annex 2 acceptance is Q4 2026 to Q1 2027. ANVISA follows in H1 2027 to H2 2027.

    For sponsors making 2026 country sequencing decisions today, the implication is straightforward. Argentina is positioned as the natural lead LATAM jurisdiction for Annex 2-aligned protocols. Brazil follows. Mexico and Colombia continue to be evaluated case-by-case based on therapeutic-area depth and sponsor-specific requirements.

    The Bottom Line

    Latin America is no longer at the edge of global GCP. The June 3 Rio Assembly, the ANVISA hosting of the meeting, and the Step 4 advancement of E6(R3) Annex 2 together signal a structural shift that sponsors building modern trial designs should integrate into 2026-2027 strategy now rather than after the fact.

    The most expensive country sequencing decision is not the one made wrong. It is the one made too late, after the trial design has been frozen and the regulatory pathway is already constrained by choices that no longer reflect the current landscape.

    If you are evaluating an Annex 2-aligned FIH protocol for 2026 or 2027 and want a LATAM country sequencing analysis that integrates the new Rio Assembly outcomes, the team at bioaccess® can produce a tailored proposal within two weeks. We have run first-in-human and pivotal-stage trials across Argentina, Brazil, Colombia, Mexico, and Panama since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • $8 Billion Of Pharma Capital Just Pointed At Argentina. What Medtech Founders Should Take From The May 29 CAEME Announcement.

    On May 29, 2026, the Cámara Argentina de Especialidades Medicinales (CAEME) announced jointly with President Javier Milei a six-year clinical research investment commitment from seven multinational pharmaceutical companies: Pfizer, Merck, Roche, Novartis, BMS, GSK, and Sanofi. The total commitment is USD 8 billion through 2032. On the same week, ANMAT’s Disposición 2978/2026, which cut import tariffs on medicines and medical devices by 50 to 70 percent, came into operative effect on June 1.

    For a Latin American clinical research operator that has spent 16 years arguing the case to MedTech and biotech founders, the May 29 to June 1 sequence is the strongest sovereign-level signal a Latin American country has produced for clinical research in the past decade. The data and the policy arrived in the same week. The Big Pharma capital and the regulator’s tariff cut arrived in the same week. The case Argentina has been building since Disposición 7516/25 first came into force in 2025 is now publicly endorsed by both seven multinational CEO offices and the federal executive.

    The interesting question is not whether founders should use Argentina for first-in-human (FIH) work. The interesting question is what happens to the Argentine clinical research ecosystem when USD 8 billion of pharma capital flows into a site base that, in 2026, has only 80 to 120 actively credentialed Phase 1/2 sites. This post unpacks the saturation thesis and what early-stage MedTech founders should be doing about it in 2026.

    The Site Saturation Math

    The CAEME pledge of USD 8 billion over 2026 to 2032 implies an average commitment of approximately USD 1.33 billion per year. At industry-average sponsored Phase 1 through 3 trial costs of USD 1 to 3 million per site per year for clinical operations and site fees, the pledge fully funds roughly 430 to 1,330 new trial-site-years annually if disbursed at the announced pace.

    Argentine clinical research currently runs at roughly 290 ANMAT-authorized trials per year (2025 throughput), with 1,188 active studies under ANMAT supervision and approximately 80 to 120 actively credentialed Phase 1/2 sites across all therapeutic areas. The pledge contemplates a 2.5x step-up in trial inflows against approximately the same site base.

    The implication is straightforward. By 2027, Argentine Phase 1/2 site capacity becomes the binding constraint on the system. Regulator throughput, which is already operative at 62 calendar days under Disposición 7516/25, is no longer the rate-limiting step. Site availability is. And site availability at top investigators compresses asymmetrically. A senior PI running three trials in 2026 does not move to six trials in 2027. A senior PI running three trials moves to four trials, while the marginal Phase 1/2 site backlog elongates by 6 to 12 months for the founders arriving last.

    Founders who lock in Argentine site relationships in 2026 are locking in the top quartile of investigators. Founders who arrive in 2027 are competing for what is left after Pfizer, Novartis, and the other CAEME signatories have claimed the senior beds.

    Why the Argentine Government Did This Now

    Three forces converged in 2026 that made the May 29 to June 1 sequence possible. First, the Milei administration’s broader productivity and quality agenda, codified in the proposed PCT (Productividad, Calidad y Transparencia) bill, created the legislative context for industry investment commitments. Second, ANMAT’s operational reform sequence, beginning with Disposición 7516/25 (62-day pathway, parallel ethics plus agency review, ICH E6(R3) alignment), reached a level of regulator credibility that multinationals could underwrite. Third, the comparative landscape moved against Argentina’s peer regulators. Colombia’s Ley 191 stalled in Comisión Séptima and is now effectively dead this term. Brazil’s ICH E6(R3) adoption remains on a slower trajectory than ANVISA’s 2024-2025 board sessions suggested. Mexico’s 30-day target announced at AMIIF on May 19 lacks DOF formalization. Argentina is the only major LATAM jurisdiction in 2026 with operative regulatory reform, operative tariff policy, and operative sovereign-level industry commitment in the same week.

    The PCT bill is the only caveat that matters. The CAEME pledge is contingent on PCT passage. As of June 1, the bill remains stalled. Founders evaluating Argentine sites should treat the regulatory and tariff case as the base case and the CAEME pledge as additive upside. Disposición 7516/25 and Disposición 2978/2026 are in force regardless.

    How to Sequence Argentina in 2026

    The country sequencing decision a MedTech founder makes in 2026 is structurally different than the same decision in 2024. Two years ago, the case for Argentine FIH rested on cost (USD 15,000 to 35,000 per patient versus USD 40,000 to 75,000 in the U.S. and Europe) and regulator throughput (62 days under 7516/25 versus 120 to 180 days under FDA EFS). Both arguments still apply, and the Disposición 2978/2026 tariff cut now removes a 4 to 8 percent additional cost layer on imported devices and study drugs.

    What is new in 2026 is the time pressure. The CAEME pledge does not change the operational case. It changes the urgency of the operational case. A founder who has been considering Argentine site selection for the past six months and has not yet executed is, beginning June 1, 2026, on the wrong side of a closing window. By Q4 2026, the same site relationships will be visibly competitive. By Q2 2027, the top-quartile PI list will be substantively claimed.

    For structural heart and cardiovascular device programs, the recommended sequence is Argentine site selection initiated by Q3 2026, ANMAT protocol filing by Q4 2026, first patient enrolled in Q1 2027. This sequence preserves access to the InCor São Paulo, Hospital Italiano Buenos Aires, and Fundación Cardiovascular Bogotá tier of cardiovascular research centers, with the Argentine arm operating in parallel with a U.S. EFS submission.

    For neuromodulation programs, the recommended sequence compresses further. Site selection at seed close (or post-Series A), ANMAT protocol filing within 90 days of site lock-in. The neuromodulation patient base in Argentina is concentrated at fewer specialized institutions than cardiovascular work, and the saturation pressure on neuromodulation-credentialed PIs is therefore more acute. Founders who have not selected Argentine neuromodulation sites by end of 2026 will likely face 6 to 9 month delays in 2027.

    For radiopharmaceutical and theranostics programs, the operational sequence is different in kind. Site selection has to be scoped before ANY other operational step because of isotope logistics, central pharmacy capacity, and credentialed nuclear medicine institutions. Radiopharma founders who wait until post-acceleration or post-Series A to scope LATAM partners have already added 6 to 9 months to their pivotal timeline. The Argentine radiopharma site base is even more concentrated than the neuromodulation base, and the CAEME pledge is highly likely to direct radiopharma-adjacent investment into the same handful of credentialed institutions.

    What This Means for the Colombia Case

    For bioaccess® and for any founder using a LATAM CRO with Colombian site depth, the May 29 to June 1 sequence forces an honest reassessment. Colombia in 2026 holds the following: established U.S.-trained PI density at specific institutions (Fundación Cardioinfantil, Fundación Valle del Lili, Universidad Javeriana), strong therapeutic-area depth in cardiovascular and oncology, INVIMA throughput at roughly 90 to 120 days. Colombia does not hold: operative sovereign-level investment commitment, modern ICH E6(R3) framework alignment (Resolución 8430/1993 remains the operative framework), or a recent tariff reduction comparable to Disposición 2978/2026.

    The Colombia case for 2026 is no longer “cheaper and faster.” The Colombia case is “specific therapeutic-area depth, U.S.-trained PI networks, and complementarity to an Argentine arm.” For founders running cardiovascular or oncology programs requiring U.S. data acceptance under FDA IDE pathways, the Colombian PI base remains uniquely qualified. For founders running neuromodulation or radiopharmaceutical programs at the FIH stage, the Argentine arm is now the primary recommendation, with Colombian sites operating as the complementary geography rather than the primary geography.

    This is a more nuanced positioning than the one bioaccess® and other LATAM CROs have historically used. It is also the positioning that will hold up over the next 12 to 18 months as the Argentine site saturation pressure builds.

    What Founders Should Do Before End of Q3 2026

    For MedTech, biotech, and radiopharma founders who have not yet scoped their LATAM site portfolio, the practical sequence over the next 90 days looks like:

    First, identify whether the program’s FIH country sequence is Argentina-primary, Argentina-secondary, or Argentina-complementary based on therapeutic area, regulatory pathway, and capital constraints. For structural heart and cardiac ablation, Argentina-primary or Argentina-secondary makes sense. For neuromodulation, Argentina-primary. For radiopharma, Argentina-primary with explicit isotope logistics scoping. For oncology devices with U.S. IDE pathway requirements, Argentina-complementary alongside Colombia or Brazil.

    Second, scope site availability at the institutions most likely to be impacted by the CAEME pledge. The largest pharma signatories (Pfizer, Roche, Novartis) historically work with a specific set of Argentine investigators in cardiology, oncology, and metabolism. Site availability at those investigators will compress first.

    Third, file ANMAT protocols on the Disposición 7516/25 parallel-review pathway. The 62-day timeline allows a 2026 Q3 site selection to produce first-patient-in by year-end. Delays beyond Q3 begin pushing first-patient-in into Q2 2027, by which point the competitive pressure on senior PIs will be visible in enrollment delays.

    Fourth, consider the Disposición 2978/2026 tariff cut as a planning input. The 50 to 70 percent reduction on imported devices and study drugs is most material for early-stage MedTech programs that import 80 to 100 percent of investigational supply. Plan device manufacturing and shipment timing to maximize the tariff savings.

    The Bottom Line

    Argentina did not become a clinical research hub on May 29, 2026. Argentina has been a clinical research hub for 30 years. What happened on May 29 to June 1, 2026, is that the federal executive, the regulator, and seven multinational pharma CEOs publicly aligned on the same operational thesis in the same week. That alignment compresses the founder decision window from years to quarters.

    For early-stage MedTech, biotech, and radiopharma founders evaluating LATAM FIH strategy, the operational reality is that the next 12 to 18 months are a sponsor-favorable market with multiple jurisdictions actively recruiting trial volume. Sponsors who position now benefit from regulator attention, expedited review windows, and access to the senior PI base. Sponsors who delay lose that window.

    The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong country sequence for their specific program. Argentina’s May 29 to June 1 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 LATAM FIH country sequencing decision and want a tailored proposal that incorporates the new ANMAT regulatory and tariff environment alongside Colombian and Brazilian complementary site options, the team at bioaccess® can produce a country-level model within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Leveraging ANMAT for Market Access: Essential Steps for Success

    Leveraging ANMAT for Market Access: Essential Steps for Success

    Introduction

    Navigating the complex landscape of market access in Argentina necessitates a profound understanding of the pivotal role played by ANMAT, the nation’s regulatory authority. Companies aspiring to introduce medical devices, pharmaceuticals, or food products must not only comply with stringent safety and efficacy standards but also adeptly leverage ANMAT’s guidelines to facilitate their entry into the market.

    However, with evolving regulations and specific documentation requirements, businesses face the pressing question: how can they effectively meet these challenges and secure a successful foothold in Argentina’s dynamic healthcare sector?

    Understand ANMAT’s Role in Market Access

    The agency plays a crucial role in ensuring that medical devices, pharmaceuticals, and food products meet stringent safety and efficacy standards before entering the Argentine market. Its authority encompasses the evaluation of clinical trials, the approval of marketing authorizations, and the enforcement of health regulations.

    To successfully navigate the entry pathway, businesses must thoroughly understand the guidelines and procedures established by the regulatory body, . This includes recognizing the classification of products into four risk categories:

    1. Class I (low risk)
    2. Class II
    3. Class III
    4. Class IV (highest risk)

    Additionally, businesses must prepare the necessary documentation, which must include a detailing the product’s design and intended application. Timelines are also critical; for instance, , while Class III and IV devices may require up to 110 working days for documentation assessment.

    Familiarity with these procedures not only facilitates compliance but also enhances the likelihood of , particularly by . Furthermore, it is essential to note that the agency is classified as a level four regulatory authority by PAHO, akin to the US FDA, necessitating that producers appoint a local representative for the registration process.

    Understanding the , which range from 0 to 16 percent, is also vital for companies considering entry into the sector. By leveraging bioaccess®’s extensive , including Early-Feasibility Studies, , and Post-Market Clinical Follow-Up Studies, companies can streamline the process of meeting and achieve successful market access. Bioaccess®’s expertise and tailored approach further bolster the ability to effectively navigate these regulatory challenges.

    The central node represents ANMAT's role, while branches illustrate crucial aspects such as product classifications and processes for regulatory compliance. Each category shows how it fits into the overall market access pathway.

    Identify Key ANMAT Requirements for Market Access

    To successfully navigate ANMAT for market access, companies must prepare several essential documents:

    • : Demonstrating the safety and efficacy of the product through well-structured clinical trials is imperative. Approximately 85% of clinical studies in Argentina successfully obtain ethics committee approval, underscoring the significance of strong in the approval procedure. bioaccess® specializes in managing Early-Feasibility Studies (EFS), (FIH), Pilot Studies, , and (PMCF). This meticulous gathering and presentation of directly influences the speed of access.
    • (GMP) Compliance: Adhering to ANMAT’s standards for production methods is essential. Compliance with GMP ensures that products are consistently produced and controlled according to quality standards, a fundamental requirement for market authorization. bioaccess® offers customized advice on GMP regulations, assisting clients in optimizing their approval process and enhancing product quality.
    • Product Labeling: Companies must ensure that product labeling meets specific , including comprehensive product information, usage instructions, and safety warnings. Proper labeling is vital for consumer safety and regulatory compliance. bioaccess® assists in developing compliant labeling strategies that align with local regulations.
    • : A comprehensive application must be submitted, encompassing all necessary documentation and evidence. Leveraging ANMAT for market access is essential, as the typical duration for authorization of clinical trial applications can extend beyond several months; therefore, thorough preparation is crucial for a seamless submission and timely approval. bioaccess®’s expertise in can significantly expedite this process, helping companies navigate the complexities of the application efficiently and connect with top-ranked clinical research sites.

    Understanding these requirements is critical for companies aiming to achieve successful market access in Argentina, especially in light of recent regulatory changes that have , making the country an increasingly attractive location for clinical research.

    The center shows the main goal of achieving market access, with branches leading to each requirement. Each branch breaks down further into specifics, helping you understand the steps involved in navigating ANMAT's regulations.

    Implement Strategies for Navigating ANMAT Regulations

    To effectively navigate , consider the following strategies:

    • Engage Local Experts: Collaborating with is essential. Their expertise can significantly improve adherence and streamline the submission process, increasing the likelihood of approval. At bioaccess, we offer comprehensive , including feasibility and selection of research sites and principal investigators, ensuring you have the right support.
    • Stay Informed: Regularly is crucial. This proactive approach allows companies to adapt their strategies promptly, ensuring alignment with the latest requirements. Our team at bioaccess provides ongoing feedback on study documents, including detailed reviews to ensure compliance with country requirements, keeping you informed.
    • Prepare Thoroughly: is key. Ensuring that all documentation is complete and accurate before submission minimizes the risk of delays or rejections, facilitating a smoother approval experience. bioaccess assists with , including detailed guidance through , to streamline your efforts.
    • Utilize Technology: Implementing . Such tools assist in monitoring submissions, deadlines, and , offering real-time insight into the regulatory landscape. At bioaccess, we also focus on study project management and monitoring, ensuring that you have the tools necessary for effective oversight.

    By adopting these strategies and leveraging ANMAT for market access, companies can significantly enhance their chances of successful entry in Argentina, confidently navigating the complexities of regulations while benefiting from our tailored support.

    The central node represents the main goal, with each branch outlining a specific strategy. Follow the branches to see detailed actions for effectively navigating regulations.

    Monitor Regulatory Changes and Adapt Strategies

    To ensure ongoing compliance and successful , companies must undertake several critical steps:

    • Establish a : Implementing a robust system to monitor —including new guidelines, amendments, and updates from , the Colombia National Food and Drug Surveillance Institute—is essential. This proactive strategy enables organizations to stay ahead of regulatory requirements, significantly reducing the risk of , which can average $220,000 per breach. Notably, 70% of service organizations reported the necessity to demonstrate adherence to at least six distinct frameworks in 2023, highlighting the complexity of regulatory requirements.
    • Regular Training: Conducting frequent on the latest regulatory requirements and best practices, particularly those outlined by , is crucial. Organizations that invest in corporate data security training can save an average of $2.54 million, underscoring the .
    • Feedback Loop: Establishing a to learn from past submissions and adapt future strategies based on experiences and outcomes is vital. This iterative process not only enhances adherence but also fosters a culture of continuous improvement. The repercussions of inadequate adherence management can be severe, underscoring the importance of learning from previous submissions.
    • Engage with Industry Groups: Actively participating in industry associations or forums that focus on regulatory issues, including those related to ‘s oversight of medical devices, offers significant advantages. and collective experiences that can inform your adherence strategies and deepen your understanding of the regulatory landscape. Furthermore, 60% of risk and governance experts plan to focus on cybersecurity education in the next two to three years, emphasizing the growing importance of collaboration in regulatory strategies.

    By diligently monitoring and adapting to from , companies can maintain compliance and significantly enhance their strategies by leveraging ANMAT for , ultimately facilitating faster enrollment and successful product launches.

    Each box represents a critical step in the process of adapting to regulatory changes. Follow the arrows to understand how each step leads to the next, ultimately guiding companies towards successful compliance.

    Conclusion

    Navigating the complexities of ANMAT is essential for companies seeking market access in Argentina. Understanding the regulatory framework and the specific requirements set by ANMAT significantly enhances the chances of successful entry into this dynamic healthcare sector. By leveraging ANMAT’s guidelines, businesses can ensure that their medical devices, pharmaceuticals, and food products meet the necessary safety and efficacy standards, ultimately paving the way for a successful market launch.

    Key insights from this guide highlight the importance of:

    • Thorough preparation
    • Adherence to Good Manufacturing Practices
    • Necessity of robust clinical evidence

    Companies must also recognize the significance of:

    • Proper documentation
    • Timely submissions to facilitate a smoother approval process

    Engaging local experts, staying informed about regulatory changes, and implementing effective strategies are pivotal steps that can streamline compliance and enhance the likelihood of approval.

    In a rapidly evolving regulatory landscape, companies must remain vigilant and proactive in adapting their strategies. By establishing a regulatory intelligence system, investing in team training, and engaging with industry groups, organizations can navigate ANMAT regulations more effectively. Ultimately, leveraging ANMAT for market access not only ensures compliance but also fosters innovation and growth within Argentina’s healthcare market, encouraging companies to take the necessary steps toward successful product launches and improved patient outcomes.

    Frequently Asked Questions

    What is ANMAT’s role in market access for medical devices and pharmaceuticals in Argentina?

    ANMAT (National Administration of Medicines, Food and Medical Technology) ensures that medical devices, pharmaceuticals, and food products meet safety and efficacy standards before entering the Argentine market. This includes evaluating clinical trials, approving marketing authorizations, and enforcing health regulations.

    How are products classified by ANMAT?

    ANMAT classifies products into four risk categories: Class I (low risk), Class II, Class III, and Class IV (highest risk).

    What documentation is required for market access through ANMAT?

    Businesses must prepare a comprehensive technical dossier that details the product’s design and intended application to comply with ANMAT’s requirements.

    What are the timelines for product evaluation by ANMAT?

    ANMAT evaluates and approves Class I and II medical devices within 15 working days. Class III and IV devices may take up to 110 working days for documentation assessment.

    What is the significance of appointing a local representative for the registration process?

    As ANMAT is classified as a level four regulatory authority by PAHO, similar to the US FDA, it is necessary for producers to appoint a local representative to facilitate the registration process.

    What are the import tax rates for medical devices in Argentina?

    Import tax rates for medical devices in Argentina range from 0 to 16 percent.

    How can companies streamline the process of meeting regulatory requirements?

    Companies can leverage bioaccess®’s clinical trial management services, including Early-Feasibility Studies, First-In-Human Studies, and Post-Market Clinical Follow-Up Studies, to effectively navigate regulatory challenges and achieve successful market access.

    List of Sources

    1. Understand ANMAT’s Role in Market Access
      • tevausa.com (https://tevausa.com/daily-news/jun-12-2025)
      • lifescienceleader.com (https://lifescienceleader.com/doc/argentina-s-thriving-medical-device-market-amid-an-economic-plunge-0001)
      • trade.gov (https://trade.gov/country-commercial-guides/argentina-medical-products)
      • Current Trends in Argentina Medical Device Trials and Regulations | bioaccess® (https://bioaccessla.com/blog/current-trends-in-argentina-medical-device-trials-and-regulations)
      • insights.citeline.com (https://insights.citeline.com/pink-sheet/product-reviews/approvals/argentina-speeds-up-market-access-process-5266SWGSGRHYNFZIGVCGU5RLU4)
    2. Identify Key ANMAT Requirements for Market Access
      • gpcgateway.com (https://gpcgateway.com/common/news/Mjc-/QXJnZW50aW5h)
      • medpace.com (https://medpace.com/blog/clinical-research-in-argentina)
      • institutocer.com.ar (https://institutocer.com.ar/en/blog/argentina,-an-ideal-destination-to-develop-clinical-trials)
      • bioaccessla.com (https://bioaccessla.com/br/blog/understanding-anmat-requirements-for-medtech-clinical-trials-an-in-depth-tutorial)
      • qreg.co.uk (https://qreg.co.uk/argentina-regulatory-requirements)
    3. Implement Strategies for Navigating ANMAT Regulations
      • pureglobal.com (https://pureglobal.com/markets/argentina)
      • How to Design Clinical Trials for Medical Devices in Argentina: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/how-to-design-clinical-trials-for-medical-devices-in-argentina-a-step-by-step-guide)
      • meddeviceonline.com (https://meddeviceonline.com/doc/will-argentina-be-the-next-medtech-clinical-trial-destination-in-latin-america-0001)
      • freyrsolutions.com (https://freyrsolutions.com/global/regulatory-services-in-argentina)
      • lspedia.com (https://lspedia.com/regulation/argentina)
    4. Monitor Regulatory Changes and Adapt Strategies
      • fiscalnote.com (https://fiscalnote.com/blog/regulatory-tracking-developing-a-winning-strategy)
      • zluri.com (https://zluri.com/blog/key-compliance-statistics-and-insights-for-2024)
      • 100+ Compliance Statistics You Should Know in 2026 (https://sprinto.com/blog/compliance-statistics)
      • 130+ Compliance Statistics & Trends to Know for 2026 (https://secureframe.com/blog/compliance-statistics)
      • ethico.com (https://ethico.com/blog/compliance-in-a-changing-landscape-adapting-to-regulatory-shifts)

  • Argentina Just Cut Clinical Trial Import Costs By 50 70%. Here’s What 290 Authorized Trials In 2025 Tell Founders.

    On May 19, 2026, Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) published Disposición 2978/2026, cutting import tariffs on medicines and medical devices by 50 to 70 percent, effective June 1, 2026. The preamble of the instrument states the policy goal explicitly: to attract clinical trial investment to Argentina. The next day, the Argentine government released throughput data that explained why the policy was built: 290 clinical trials authorized in 2025, a 12 percent year-over-year increase, with 114 already authorized in the first quarter of 2026 and 1,188 active studies under ANMAT supervision. Argentina is now formally branding itself an “internationally competitive clinical research hub.”

    For a Latin American clinical research operator who has spent 16 years arguing the speed-and-cost case to MedTech and biopharma founders, the May 19-20 sequence is the most unusual validation event the regulatory landscape has produced this decade. Most LATAM clinical research positioning is CRO marketing. Argentina’s came from the regulator itself, in the preamble of a binding instrument, on government letterhead, with throughput numbers attached. That is not the same kind of evidence as a competitive pitch deck.

    For founders running a 10-patient first-in-human (FIH) device study, the math now stacks in a way that materially changes the country sequencing decision. This post unpacks what changed, what stayed the same, and how founders pursuing a U.S. Early Feasibility Studies (EFS) plus out-of-U.S. (OUS) FIH strategy should think about Argentina in 2026.

    What Changed on May 19, 2026

    Disposición 2978/2026 is the binding instrument. The tariff reduction applies across the import basket relevant to clinical research operations, including investigational drugs, medical devices in trial-supply quantities, reference standards, and disposable consumables tied to study protocols. The pre-existing effective duty rate for imported medical devices in Argentina ranged from 12 to 18 percent before May 19. Under the new schedule, that effective rate compresses to roughly 6 to 12 percent for trial-supply imports, with category-specific reductions ranging from 50 to 70 percent depending on the harmonized system classification.

    On its own, the tariff cut is meaningful. It is more meaningful in combination with the operational baseline Argentina already had in place. Disposición 7516/2025, which came into force in 2025 and is fully aligned with ICH E6(R3), caps clinical trial protocol authorization at 62 calendar days (45 working days maximum). That includes parallel ethics committee review and ANMAT agency review, not sequential review. For comparison, the U.S. EFS pathway typically runs 120 to 180 days from IDE submission to first patient enrolled. Argentina’s ANMAT pathway is 60 to 120 days faster, depending on the comparison case.

    The April 24, 2026 importación simplification further compresses pre-first-patient timelines by removing roughly 14 to 21 days of customs and import-classification delay that previously sat between protocol approval and the actual arrival of study material at site. The June 1, 2026 tariff reduction now removes the cost penalty that previously sat alongside that delay.

    The Throughput Number Most Founders Miss

    The 290-trials-in-2025 figure deserves more attention than it has received. Of those 290 authorizations, the regulator-reported mix is approximately 70 percent biopharma and 30 percent medical device or combination product. The Q1 2026 pace of 114 authorizations annualizes to roughly 456 trials per year, which would represent a 57 percent year-over-year acceleration if sustained. Even if the run rate moderates by half, Argentina’s 2026 throughput will exceed all prior years on record.

    For a founder evaluating site capacity risk, the 1,188 active studies under ANMAT supervision is the more strategic data point. Argentina has the patient-volume depth and the principal-investigator network density to absorb new sponsor demand without the recruitment friction that emerging-market sites with thinner trial histories often impose. A FIH MedTech sponsor running a 10-patient study at two Argentine sites can realistically expect first-patient-in within 90 days of protocol approval, and last-patient-in within 5 to 7 months of contract execution. Those numbers have been stable across the last 36 months of bioaccess® operational experience.

    The Cost Math, Refreshed

    Pre-May 19, 2026, the LATAM per-patient cost range for a FIH MedTech study sat at $15,000 to $35,000, compared to $40,000 to $75,000 in the U.S. and Europe. For a 10-patient FIH device study, that is a $250,000 to $400,000 absolute swing, sufficient on its own to fund roughly four months of clinical operations headcount or a complete adaptive design biostatistics package.

    The June 1 tariff reduction does not move the per-patient labor cost. It moves the device and drug-import cost component, which typically represents 8 to 15 percent of total study cost for a MedTech FIH trial relying on imported investigational devices. A 50 percent reduction on that line item produces a 4 to 8 percent reduction on total study cost, which compounds with the labor cost advantage Argentina already offered. On a $250,000 study, that is an additional $10,000 to $20,000 of effective savings. On a $1 million pivotal-stage Argentine arm of a multi-country trial, the effect grows proportionally.

    The strategic value is not the headline savings number. It is the regulatory clarity that the tariff cut produces. Sponsors evaluating Argentina now know that the regulator has formally committed to clinical research as a strategic policy priority. That changes how a CFO evaluates jurisdiction risk in the IND-enabling phase.

    The Database Anomaly and How to Work Around It

    One operational caveat is worth flagging directly. ANMAT’s public pharmacology database, which historically served as the citable reference for trial throughput and status, remains anchored at a September 30, 2025 data cutoff. As of the publication date of this post, that anomaly has persisted for four consecutive weekly review cycles. The most likely explanation is a backend migration tied to the broader Argentine government’s digital transformation initiative, but the database itself does not yet reflect Q4 2025 or any 2026 data.

    For sponsors building a regulatory dossier or a board pack that requires citable Argentine clinical research throughput data, the May 20, 2026 government statistics package, available through argentina.gob.ar communications channels, is now the more authoritative source than the database. For real-time individual study status, the RENIS (Registro Nacional de Investigaciones en Salud) registry, accessible through the SISA portal, remains operative and current. Disposición 7516/25, the 62-day pathway, the importación simplification, and Disposición 2978/2026 are all fully in force regardless of the database refresh status.

    How to Sequence Argentina in a U.S. EFS Plus OUS FIH Strategy

    The most common 2026 founder question is whether to run U.S. EFS first, OUS FIH first, or both in parallel. The May 19-20 Argentina updates do not change the answer in every case, but they change it in enough cases that the question is worth re-examining.

    For structural heart, neuromodulation, and radiopharmaceutical or theranostic FIH programs, where the U.S. EFS pathway involves an IDE submission with 120 to 180 day review timelines, the parallel Argentina arm is now substantially more attractive. The argument runs as follows: a sponsor who files the IDE with FDA in month one and simultaneously files the ANMAT protocol under Disposición 7516/25 will, in a typical case, have ANMAT approval and first-patient-in achieved before the FDA has finished its initial IDE review. That bridge data, if collected against an FDA-aligned endpoint set, materially strengthens the IDE review and accelerates the post-IDE clinical trial path.

    The bridge data approach assumes the sponsor designs the Argentine arm to match the FDA-expected endpoints from the outset. That is not a regulatory obligation in Argentina, but it is the operational discipline that converts a 62-day pathway into a strategic asset rather than a parallel cost center. ICH M11 CeSHarP, finalized by ICH on May 21, 2026, makes that endpoint-aligned protocol authoring substantially more efficient than it was a year ago.

    For absorbable implants, cardiac ablation, and oncology device FIH programs, the Argentina arm makes sense as the primary FIH site set, with the U.S. EFS following as a confirmatory phase rather than as the primary first-in-human exposure. The 2026 tariff reduction further tips the math in this direction for sponsors with capital constraints between Series A and Series B.

    What This Means for the Latin American Clinical Research Landscape

    Argentina’s May 19-20 sequence is the clearest example to date of a Latin American regulator choosing, in policy, to compete for clinical research investment. Brazil, Mexico, and Colombia have made similar moves in the past 24 months, but none have packaged a binding tariff reduction with a coordinated government statistics release in the same week. The combination is what makes the Argentine moment unusual.

    For Latin American CROs, the strategic implication is that the next 12 to 18 months will likely be a sponsor-favorable market, with multiple jurisdictions actively recruiting trial volume. Sponsors who position now will benefit from regulator attention, expedited review windows, and the willingness of agencies to engage with novel trial designs at the pre-submission stage. Sponsors who delay until the policy environment has fully stabilized will lose the strategic window.

    For bioaccess® and other LATAM operators, the implication is that the value proposition has moved beyond cost and speed into regulatory partnership. The conversation a founder needs to have with their CRO in 2026 is no longer about how fast the trial can run. It is about how the trial design, the country sequence, and the data architecture combine to compress the Innovation Runway, the operational window between a founder’s first FIH decision and the data package their next funding round requires.

    The Bottom Line for Founders

    Argentina has just made the clearest policy statement any Latin American clinical research regulator has produced in 2026. The 62-day pathway under Disposición 7516/25 is operative. The importación simplification is in force. The 50 to 70 percent tariff reduction on imported medicines and medical devices begins June 1. The throughput data confirms that the regulatory environment can absorb new sponsor demand at scale.

    For a MedTech, biotech, or radiopharma founder evaluating a 2026 FIH country sequencing decision, the Argentine arm now warrants serious consideration as the lead site or the parallel site for any program where the U.S. EFS pathway is the comparison baseline. The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong study to run first. Argentina’s May 19-20 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 FIH sequencing decision and want a country-level model that reflects the new Argentina policy environment, the team at bioaccess® can produce a tailored proposal within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations: